Recent epidemics of Ebola virus disease in Africa have increased the potential risk of Ebola virus transmission via donated blood and blood components, cells, tissues and organs (substances of human origin; SoHO), not only locally and regionally in Africa, but also in non-endemic unaffected areas such as Europe due to population movements.
This technical report assesses the risk of Ebola virus transmission through substances of human origin and offers guidelines on the safety of donations where the potential donors are travellers returning from Ebola-affected countries, people exposed to Ebola virus or patients who have recovered from the disease.
This first update of the original guide was prompted by the evolution of the Zika virus epidemic, a new classification system for countries/areas, and recent scientific developments.
ECDC is following reports from several European Union and European Economic Area (EU/EEA) countries of substantial increases in the detection of parvovirus B19 (B19V).
The European Centre for Disease Prevention and Control (ECDC) has released a Threat Assessment Brief highlighting an increase in reported parvovirus B19 (B19V) infections across 14 European Union and European Economic Area (EU/EEA) countries.
On 31 May 2024, the European Medicines Agency (EMA) published the Committee for Medicinal Products for Human Use (CHMP) reflection paper on Creutzfeldt-Jakob disease (CJD) and plasma-derived and urine-derived medicinal products.
This ECDC survey protocol describes the technical requirements for implementing a genomic surveillance-based survey of CRAb isolates from patients seeking hospital care. It is intended for first use in 2024–2025.